Tracks heart and lung changes over time using ultrasound and AI
Observes whether ultrasound and AI can spot worsening in adults with heart conditions.
Key facts
- Who runs it
- Truway Health, Inc.
- Where
- New York, United StatesSee the site
- Trial code
- Registry title
- Multimodal Physiologic State Intelligence Study
- Status
- Enrolling by invitation
- People taking part
- 25,000 people, planned
- Started
- 2 Sept 2026
- Expected to end
- 15 Sept 2046
- Type of study
- Observational
- Treatments tested
- OMNIPHYS Multimodal Ultrasound Imaging System
- Record updated
- 10 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who are having routine heart, blood vessel, lung, kidney or other medical care. Healthy volunteers can also join as reference participants.
- Age
- 18 years or older
- Sex
- All sexes can join
Main reasons for not taking part
- Cannot give informed consent or meet the consent requirements
- Scans or measurements the study needs cannot be read clearly
- The study investigator judges that taking part is not appropriate
- Cannot be followed over time in a meaningful way
- Withdrew consent
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Adults aged 18 years or older who are capable of providing informed consent, or who meet applicable legally authorized representative requirements where permitted
- Individuals undergoing routine clinical evaluation, diagnostic imaging, monitoring, treatment, or longitudinal follow-up, including individuals with relevant cardiovascular, vascular, pulmonary, renal, systemic, or other conditions represented within the OMNIPHYS research framework
- Healthy volunteers without the conditions under study may participate as reference participants
- Ability to undergo at least one protocol-relevant physiologic or imaging assessment and/or contribute eligible routinely collected clinical data
- Availability of sufficient clinical, physiologic, imaging, or longitudinal outcome data for the applicable analysis
- Willingness to permit collection and longitudinal analysis of protocol-defined research data in accordance with informed consent and applicable privacy and data-governance requirements
Who cannot take part
- Conditions or circumstances that, in the judgment of the responsible clinical investigator, make participation inappropriate or prevent meaningful longitudinal follow-up
- Inability or unwillingness to provide informed consent or otherwise meet applicable consent requirements
- Inability to obtain interpretable protocol-relevant physiologic or imaging data when such data are required for the applicable analysis
- Withdrawal of consent or request for discontinuation of research participation where applicable
- Any circumstance that would prevent collection, secure handling, or analysis of study data in accordance with the approved protocol and applicable requirements
Where in United States
- Truway Health, Inc.New York, United StatesEnrolling by invitation
About the trial
What the trial wants to find out
The OMNIPHYS study will investigate whether multimodal ultrasound and other routinely collected clinical and physiologic data can be combined with artificial intelligence to characterize changes in a person's physiologic state over time. The study will examine cardiac, vascular, pulmonary, and systemic physiologic measurements and develop longitudinal models that describe baseline physiology, physiologic perturbation, compensation, deterioration, treatment response, and recovery. The study is observational and will not assign experimental treatments. The goal is to determine whether changes in multimodal physiologic patterns can be identified and characterized earlier and more reliably than conventional single-time-point assessment.
The group in the trial
- OMNIPHYS Master Physiologic Cohort
A prospective longitudinal observational cohort of participants undergoing routine clinical evaluation and/or care. The cohort will be characterized using multimodal physiologic observations, including ultrasound-derived imaging, 2D and 3D imaging, color and spectral Doppler, cardiac and vascular measurements, pulmonary ultrasound findings, vital signs, ECG, oxygen saturation, laboratory data, medications, diagnoses, clinical encounters, and longitudinal outcomes. Participants will not be assigned to an experimental treatment. Disease-specific and physiologic subcohorts may be evaluated within the master cohort using a common longitudinal physiologic-state framework.
Treatment: OMNIPHYS Multimodal Ultrasound Imaging System
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- OMNIPHYS: A Prospective Multimodal Longitudinal Study of AI-Enabled Physiologic State Modeling and Early Detection of Clinical Deterioration
- Plain-language title
- Tracks heart and lung changes over time using ultrasound and AIGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 10 September 2026